Does Tirzepatide Weaken Your Immune System? What the Evidence Shows

You've read something online about infections and now you're not sure

This is one of the questions our prescribers hear most weeks, usually because someone has come across a forum post or a headline about GLP-1 medicines causing illness. It is worth separating what the data show from what is being inferred.

In SURMOUNT-1, the pivotal phase-3 trial published in the New England Journal of Medicine, common respiratory infections such as nasopharyngitis were recorded among participants. What matters is the comparison: these occurred at rates that were not substantially different from those seen in the placebo arm. A medicine that genuinely suppressed immunity would tend to produce a clear and consistent excess of infections across the trial. SURMOUNT-1 did not show that pattern.

Tirzepatide's pharmacology also points away from immune suppression. It works by activating two receptors (GIP and GLP-1) that regulate how the body responds to food, slows gastric emptying, and signals fullness. These receptors are not part of the machinery that controls lymphocyte activity, antibody production, or the innate immune response. There is simply no direct pathway by which tirzepatide would lower your defences in the way an immunosuppressant drug does. You can read the NHS overview of tirzepatide on the NHS medicines pages for a plain-language explanation of how the medicine acts.

One practical checking habit: if you are taking any medicine that genuinely does suppress the immune system (methotrexate, ciclosporin, biological therapies, long-term oral corticosteroids) check the list against what you disclose in your consultation. A two-minute scan of your repeat prescriptions before you fill in the form means your prescriber has the full picture from the start.

What weight loss actually does to immune function

Here is something the question rarely anticipates. Significant weight loss, sustained over months, tends to improve several markers of immune and metabolic health rather than harm them. Obesity itself is associated with a chronic low-grade inflammatory state (elevated levels of cytokines including IL-6 and TNF-alpha) and reducing excess weight can reduce that background inflammation.

The NHS guidance on obesity as a health condition notes that excess weight affects multiple body systems, the immune and metabolic included. So the indirect trajectory for most people on tirzepatide is positive rather than negative: as body weight falls and metabolic markers improve, the conditions that support healthy immune function tend to improve alongside them.

That is not a guaranteed outcome, and it is not something to treat as a reason to delay seeking medical advice if you feel unwell while on treatment. But it does provide useful context for the concern. The fear that losing weight via a GLP-1 receptor agonist will leave you more vulnerable to illness does not match the known biology.

If you are specifically interested in how tirzepatide behaves in people with pre-existing autoimmune conditions, the tirzepatide and autoimmune conditions page covers that ground in more detail.

Where genuine caution is reasonable

None of the above means there are no situations where extra care is warranted. A few things are worth flagging clearly.

Gastrointestinal side effects are common at the start of treatment and during dose increases, nausea, vomiting, diarrhoea. These are not immune effects, but severe and prolonged vomiting or diarrhoea can cause dehydration, and dehydration places stress on the kidneys and on the body more broadly. If GI symptoms are severe and not settling, that is a reason to contact your prescriber or, if the symptoms are serious, to seek urgent medical attention. The MHRA Yellow Card scheme allows patients to report any suspected side effects directly to the regulator.

People with a history of recurrent or unusual infections, or those taking medicines that genuinely do alter immune function, should make sure their prescriber knows this before treatment begins. It does not automatically rule out tirzepatide, but it is information a clinical assessment needs to account for. Some people also ask whether the body can become immune to Mounjaro over time, which is a separate question worth exploring if you are concerned about the medicine's effectiveness diminishing. There is a broader look at how tirzepatide accumulates in the body over time if you want to understand the pharmacokinetics behind that assessment.

Pregnant women, those breastfeeding, and people trying to conceive are advised not to use tirzepatide. Under-18s are also outside the licensed indication. These restrictions exist because the safety data in those groups are limited, not because of immune concerns specifically.

For a broader picture of the medicine (mechanism, eligibility, and what a private consultation involves) the Mounjaro overview is the clearest starting point. Understanding cost as part of your decision? The Mounjaro price comparison page sets out what affects the market honestly. If you are stopping treatment or managing side effects, our page on how to flush Mounjaro out of your system explains what happens as the medicine clears and what you can do to support that process. When you are ready to speak to a prescriber, start your free consultation and your answers will be read the same day by a real clinician.